Supplementary Tables – Frontline anti-PD-1/PD-L1 versus bevacizumab in advanced non-small cell lung cancer: a network meta-analysis

dataset

posted on 2022-02-07, 14:04 authored by Taylor & FrancisTaylor & Francis, Jiarui Chen, Xingyu Liu, Junhong Zhang, Zhao Huang, Wei Zeng, Jing Hu, Gang Chen, Yan Gong, Yu Liu, Conghua Xie

Supplementary Table S1–S4. Frontline anti-PD-1/PD-L1 versus bevacizumab in advanced non-small cell lung cancer: a network meta-analysis

Funding

National Natural Science Foundation of China (81773236, 81800429 and 81972852)

Key Research & Development Project of Hubei Province (2020BCA069)

Nature Science Foundation of Hubei Province (2020CFB612)

Health Commission of Hubei Province Medical Leading Talent Project, Young and Middle-Aged Medical Backbone Talents of Wuhan (WHQG201902)

Application Foundation Frontier Project of Wuhan (2020020601012221)

Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund (znpy2019001, znpy2019048, and ZNJC201922)

Chinese Society of Clinical Oncology Top Alliance Tumor Immune Research Fund (Y-JS2019-036)

History

Usage metrics

Keywords

PD-1/PD-L1 inhibitor bevacizumab chemotherapy non-small cell lung cancer combined interventions PD-L1 expression liver metastasis survival adverse events network meta-analysis Cancer Cell Biology Cancer Therapy (excl. Chemotherapy and Radiation Therapy)Chemotherapy Molecular Targets Solid Tumours

Licence

CC BY-NC-ND 4.0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM